Navigation Links
Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer.  Dr. Parsley will fill a key role on Aires' leadership team and will be responsible for all clinical development activities for Aironite™, the company's lead product for treatment of pulmonary arterial hypertension (PAH).

Dr. Parsley joins Aires from Pfizer where he was the Clinical Lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's approved drug to treat PAH, as well as the additional compounds in Pfizer's pulmonary vascular disease portfolio.  Dr. Parsley previously worked at CSL Biotherapies and Encysive Pharmaceuticals, Inc. where he was the Executive Director for Global Medical Affairs and Drug Safety developing an endothelin antagonist for pulmonary hypertension, heart failure and resistant hypertension.

Dr. Parsley is a practicing physician and Board certified in Pulmonary, Internal Medicine, Critical Care and Sleep Medicine.  Prior to joining industry, he was an assistant professor and medical director at the University of Texas Medical School at Houston.

"We are excited to welcome Ed to our team," stated Wendy Johnson, President & CEO of Aires.  "Ed brings a wealth of experience developing drugs for treatment of PAH and other pulmonary vascular diseases.  He is well-known in the PAH community and will make immediate contributions to shaping and executing our clinical development program."

About Aires

Aires Pharmaceuticals, Inc. is a privately held drug development company located in San Diego developing Aironite™ for cardiopulmonary indications such as pulmonary arterial hypertension.  In November 2010, Aires announced a $20M equity financing funded by ProQuest Investments and MPM Capital.


'/>"/>
SOURCE Aires Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. T-System Provides Free Medical Documentation Templates and Bi-Lingual Triage Questionnaires for Haiti Relief Medical Personnel
2. Buenos Aires Welcomes CPhI South America 2010
3. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
4. CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Hypermarcas S.A. ("Hypermarcas") today announced that ... "Tender Offer") to purchase any and all of ... its 6.500% Senior Notes due 2021 (CUSIP Nos. ... "Notes"). In connection with the Tender Offer, Hypermarcas ... "Consents") of the holders of the Notes (the ...
(Date:2/12/2016)... Feb. 12, 2016   HeartWare International, Inc . ... and webcast to discuss its financial results for the ... Thursday, February 25, 2016 at 8:00 a.m. ET.  The ... the conference call and webcast.  On the conference call ... highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... -- On Thursday, Feb. 11, 2016, surgeons at the ... Austin Medical Center successfully completed the first robotic surgery ... Surgical System with Trumpf Medical,s advanced operating table, the ... M.D., colorectal surgeon at the Texas Institute for Robotic ... technology, which seamlessly combines the da Vinci Xi Surgical ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... Many individuals looking to lead a healthy lifestyle have ... IsoPasta by Isolator Fitness has delved into this niche allowing those giving up ... repercussions. IsoPasta has 30 grams of protein and only 7 grams of carbohydrates ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... learn how to start an IV and draw blood, combining technology with traditional ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... According to ... surgeries are beginning to account for a significant portion of hernia repairs throughout the ... of the Beverly Hills Hernia Center notes that this trend has not only been ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television ... a demanding job, and no time to decompress, Rabinowitz found herself drawn to a ... meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with her ...
Breaking Medicine News(10 mins):